Francesco Schettini, Physician-Scientist at the Breast Unit of the Hospital Clinic of Barcelona and IDIBAPS, shared a post on LinkedIn about a paper by Nadia Harbeck et al. published in ESMO open:
“Reassuring long-term outcomes data from Nadia Harbeck and the WSG group in HR+/HER2- breast cancer, showing in the PlanB registry study:
- Similar outcomes with TC and EC-Docetaxel in pN0 or pN1 and intermediate-to-high-risk disease.
- Overall excellent 10-year OS, which was 94.2% (95% CI 88.9% to 97.1%) in RS <12 (77.9% received ET-only), 96.8% (95% CI 94.4% to 98.2%) in RS 12-25, and 96.1% (95% CI 90.9% to 98.4%) in RS >25 group.
To note, Oncotype RS was not predictive of the efficacy of EC-Docetaxel versus TC.”
Title: Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry
Authors: U. Nitz, M. Graeser, O. Gluz, S. Kümmel, M. Just, C. Jackisch, C. Zu Eulenburg, M. Christgen, N. Harbeck
You can read the full article in ESMO Open.
More posts featuring Francesco Schettini.